The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases

Table 2

Preoperative serum GLYCOV and CA125 values for primary serous epithelial ovarian cancer patients, patients suffering from benign diseases and healthy controls.

	GLYCOV value			CA125
	Mean	Median	Range	Mean	Median	Range
Controls	0.21	0.13	0–0.83	14.45	12.0	6–38
BOD	0.42	0.38	0.02–1.27	36.90	30.50	12–100
EOC patients	4.31	2.90	0.56–12.82	225.86	65.50	6–1474
FIGO stage
I	2.92	2.29	0.64–7.44	33.82	28.5	6–103
II	5.70	5.01	0.56–12.82	417.9	221.0	23–1474
Grade
I + II	4.54	3.35	0.64–12.82	259.0	30.0	6–1474
III	4.03	2.33	0.56–12.52	185.11	86	18–851